Humacyte to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Humacyte, Inc. (Nasdaq: HUMA) announced that Dale Sander, CFO, and Heather Prichard, COO, will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 10:30 a.m. ET in Miami. The conference will be available both in-person and virtually. Humacyte is a clinical-stage biotechnology company focused on developing bioengineered human tissues for medical applications. Their product, human acellular vessels (HAVs), is in late-stage clinical trials and has received FDA designations for vascular trauma and hemodialysis access.

DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Dale Sander, Chief Financial Officer, and Heather Prichard, Ph.D., Chief Operating Officer, will deliver a corporate presentation in-person at the H.C. Wainwright Global Investment Conference taking place both virtually and in-person at the Fontainebleau Hotel in Miami, on May 24, 2022, at 10:30 a.m. ET.

The webcast will be available for replay for at least 30 days following the presentation at https://investors.humacyte.com/news-events/events-and-presentations.

About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and complex tissue and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAV for arteriovenous (AV) access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Heather Anderson
6 Degrees
919-827-5539
handerson@6degreespr.com
media@humacyte.com

 

FAQ

When is Humacyte's presentation at the H.C. Wainwright Global Investment Conference?

Humacyte's presentation will take place on May 24, 2022, at 10:30 a.m. ET.

Who will present for Humacyte at the conference?

Dale Sander, the CFO, and Heather Prichard, the COO, will present for Humacyte.

What is the focus of Humacyte's biotechnology platform?

Humacyte focuses on developing universally implantable bioengineered human tissues for various medical applications.

What is the status of Humacyte's acellular vessels in clinical trials?

Humacyte's human acellular vessels are currently in late-stage clinical trials targeting multiple vascular applications.

What designations has Humacyte's HAV received from the FDA?

Humacyte's HAV received FDA's Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations.